Suvoda is a global clinical trial technology company with a market-leading, real-time software platform that empowers sponsors and CROs to make confident decisions and sites and patients to take calm, controlled action. Trusted by the world’s leading pharmaceutical and biotech companies, Suvoda is recognized as a Leader by Everest Group in its RTSM PEAK Matrix and holds five patents related to its platform architecture. The Suvoda Platform is built to keep life-changing studies moving forward, even in the most time-sensitive, mission-critical moments. The company supports more than 6,000 trials across more than 115 countries, with customer satisfaction scores that consistently exceed the technology industry average.
Learn more about Suvoda.
Suvoda builds and supports the technology that powers clinical trials. Its unified platform connects the operational and financial dimensions of a study—from randomization and drug supply management to patient data collection, informed consent, financial support for patients, and site payments—so that sponsors, CROs, sites, and patients have what they need to keep trials moving. Suvoda combines purpose-built software with industry-leading services and support, designed for the complexity of modern global clinical research. Learn more about the Suvoda Platform.
Suvoda is headquartered in Conshohocken, PA (outside Philadelphia). The company maintains offices in Portland, OR; Barcelona, Spain; Bucharest and Iasi, Romania; and Tokyo, Japan. Its platform supports trials in more than 115 countries.
Suvoda has been selected by trial sponsors and CROs to support more than 6,000 trials across more than 115 countries.
Suvoda has particular depth in therapeutic areas where clinical trials are highly complex, time-sensitive, and operationally demanding, including oncology, central nervous system (CNS) disorders, and rare diseases. Its platform is purpose-built for studies where protocol flexibility, supply precision, and patient support matter most. Suvoda supports trials across a broad range of additional therapeutic areas and study types globally.
Suvoda has received independent recognition across analyst assessments and industry awards programs, including:
In 2025, Suvoda and Greenphire combined to create a single clinical trial technology company operating under the Suvoda name. Greenphire was a leading provider of clinical trial financial management and patient support tools. Suvoda was a leading provider of clinical trial randomization, supply management, and data collection technology. The combination brought Greenphire’s patient payments, site payments, travel logistics, and budgeting and benchmarking products onto the same platform as Suvoda’s RTSM, eCOA, eConsent, and scheduling capabilities. The result is a unified ecosystem spanning the operational and financial dimensions of a clinical trial under one platform, one data layer, and one vendor relationship—reducing complexity for sponsors, CROs, and sites, and delivering a more connected experience for patients.
The Suvoda Platform combines interconnected products across clinical operations and financial management:
All products share a common data layer, enabling a unified view of the patient and reducing reconciliation across systems.
Sponsors and CROs can work with Suvoda on individual products or combinations that fit their study needs. Many customers start with RTSM, eCOA, or Patient Payments and expand to additional products. The platform’s unified architecture means that when products are used together, data flows across them automatically, reducing the need for custom integrations and cross-system reconciliation. Learn more about the platform.
When RTSM (IRT) and eCOA operate on separate systems, study teams can lose time reconciling data across vendors and miss opportunities to use patient-reported outcomes to drive real-time trial decisions. Suvoda connects both on a shared platform and data layer, enabling gates and triggers that link eCOA responses directly to supply and randomization logic. For example, a patient’s questionnaire score can automatically trigger a dosing decision or a resupply event—without manual intervention or cross-system reconciliation. See how unified eCOA and IRT work in practice.
Fragmented technology is one of the leading sources of site burden in clinical trials. According to Everest Group research sites manage an average of 22 sponsor-mandated systems within a single study, and 83% say technology burden increasingly influences their decision to participate in trials. Suvoda’s unified platform addresses this directly: products share a single login, a common data layer, and consistent user experience design. For patients, the Suvoda App consolidates visit scheduling, questionnaires, payment status, travel support, and reminders in one place on a personal device, reducing the friction that contributes to dropout and non-compliance.
Suvoda’s quality management system (QMS) covers both GxP-compliant eClinical systems and clinical trial financial and travel systems. Processes supporting our eClinical systems are designed to meet applicable requirements from regulatory and industry bodies including the FDA (21 CFR Part 11 and 21 CFR Part 312), EMA (Annex 11), and ICH (E6 R3, Good Clinical Practice). Processes supporting our financial and travel systems are designed to meet applicable requirements including PCI DSS, annual SOC 1 Type 2 assessments, and Know Your Customer (KYC). Because most Suvoda systems process personal data, including data from clinical trial participants, every process in our QMS is also designed to meet applicable data privacy and security requirements, including the EU General Data Protection Regulation (GDPR).
Details are available in the Suvoda Trust Center.
Yes. Suvoda supports integrations with a wide range of clinical trial systems, including EDC, CTMS, eTMF, and others. Learn more about Suvoda’s systems integration approach.
Suvoda’s AI approach is grounded in a core principle: AI should accelerate and support human decision-making, not replace the human judgment that clinical trials require. Suvoda’s AI capabilities operate within a validated knowledge space, enforce study-level permissions, and produce auditable outputs. Current AI deployments include Sofia, an AI assistant embedded in Suvoda RTSM and eCOA, and Agentic RTSM, which uses AI to automate and accelerate the study build and amendment process. Suvoda plans to extend agentic capabilities to eCOA and its financial services products.
Sofia is an AI assistant built into Suvoda RTSM and Suvoda eCOA. It allows study teams to retrieve trial data, get answers to operational questions, and take action through natural conversation, replacing multi-step system navigation. Sofia is designed with role-based permissions and privacy safeguards so that each user only accesses information appropriate to their role in the study. Learn more about Suvoda’s AI approach.
Agentic RTSM is Suvoda’s AI-powered approach to study build and configuration for RTSM. Rather than relying entirely on manual configuration by engineers, Agentic RTSM uses AI trained on clinical trial expertise to automate portions of the study setup and amendment process. This has demonstrated the potential to reduce kickoff-to-UAT timelines by up to 80%. Learn more at suvoda.com/our-ai-approach.
Suvoda’s AI approach is built on three principles: human oversight remains central to all AI-assisted decisions; AI operates within deterministic, expert-authored logic and role-based permissions; and all outputs are auditable and traceable. AI assists study teams by handling repetitive, time-consuming tasks while keeping domain experts in control of judgment calls. This approach aligns with the joint FDA and EMA AI principles published in January 2026.
See also: Responsible AI in clinical trials starts with how it is designed.
Suvoda’s primary customers are pharmaceutical and biotech sponsors, contract research organizations (CROs), and academic and university research institutions running complex, global clinical trials. The company is particularly well suited to studies in oncology, CNS, and rare disease, where trial complexity, supply precision, and patient support requirements are highest. Research sites and patients also interact directly with Suvoda technology throughout the trial lifecycle.
Suvoda partners closely with more than 35 CROs and has dedicated resources for CRO partnerships, including technology configurations tailored to how CROs manage studies on behalf of multiple sponsors. CROs benefit from Suvoda’s unified platform by reducing vendor fragmentation across their trial portfolios.
Suvoda helps make participating in a clinical trial easier for patients by reducing the logistical and financial burdens that can make participation challenging. Patients can manage trial-related activities such as visit reminders, eCOA questionnaires, payments, and travel support in one place. Suvoda also provides travel coordination and concierge support to help patients get to study visits and navigate the practical details of participation.
By connecting these services through a unified platform, Suvoda helps create a more convenient, supported experience for patients while helping study teams improve engagement and reduce the barriers that can contribute to missed visits, non-compliance, or dropout.
The importance of patient centricity in clinical trials is reinforced by what Suvoda hears from study teams, as well as research from Everest Group which found that organizations using patient-centric technology report stronger gains in data accuracy and completeness than non-adopters expect.
Yes. The Suvoda App is a patient-facing mobile application that consolidates the key activities a trial participant needs to manage in one place: visit scheduling and reminders, eCOA questionnaires, payments, and travel support. It is designed for use on a participant’s personal device (BYOD), reducing the need for provisioned study devices, and giving patients a consistent, accessible experience throughout the trial. For sites, the app reduces the manual coordination burden that typically falls on site staff to remind and guide participants between visits.
Yes. Greenphire Travel provides end-to-end travel and logistics support for patients and caregivers—covering rideshare, air, rail, lodging, and travel documentation, all funded upfront with no out-of-pocket costs. A global network of more than 70 dedicated Concierge Coordinators across 40+ countries provides personalized, native-language support, particularly for rare disease and oncology studies where patient needs are most complex.
Yes. RTSM (IRT) and eCOA are both core products on the Suvoda Platform and are designed to work together on a shared data layer, enabling real-time gates, triggers, and supply decisions driven by patient-reported outcomes.
Yes. Greenphire Patient Payments and Greenphire Travel are both available on the Suvoda Platform and are accessible to patients in one place through the Suvoda App.
Yes. Suvoda eCOA supports both bring-your-own-device (BYOD) and provisioned device deployments, giving sponsors and CROs flexibility to choose the approach that best fits their patient population and study design.
Yes. Suvoda RTSM is built for complex, global clinical trials and supports a wide range of randomization designs, including stratified, dynamic, and adaptive randomization schemes.
Yes. Suvoda RTSM includes predictive resupply capabilities that use real-time enrollment and consumption data to forecast demand and automate resupply decisions, helping sponsors avoid both stock-outs and excess drug waste.
Yes. Suvoda RTSM is designed to maintain blinding integrity throughout the trial lifecycle, including support for double-blind, single-blind, and open-label study designs with appropriate role-based access controls.
Yes. The Suvoda Platform supports clinical trials in more than 115 countries, with multilingual capabilities, global regulatory compliance, and offices across North America, Europe, and Asia. Contact Suvoda to discuss your global study needs.
Yes. The Suvoda Platform includes capabilities designed for decentralized and hybrid trial models, including BYOD eCOA, the patient-facing Suvoda App, remote visit scheduling, remote visits with clinicians, and direct-to-patient financial support through Greenphire Patient Payments and Greenphire Travel.
Yes. Oncology is one of Suvoda’s core therapeutic areas. The platform is built to handle the protocol complexity, adaptive designs, and patient support requirements that characterize modern oncology studies. Learn more.
Yes. Rare disease trials can present unique challenges: small patient populations, geographically dispersed sites, and patients who often face significant logistical and financial barriers to participation. Suvoda’s unified platform addresses these directly, combining RTSM, eCOA, patient payments, and travel services in one connected experience. Learn more.
Yes. The Suvoda Platform supports global studies with their language needs, including multilingual eCOA questionnaires, patient-facing interfaces, and help desk, all enabling sponsors to run consistent global trials across diverse patient and site populations. Suvoda’s concierge travel coordinators provide native-language travel services around the world.
Yes. The Suvoda Platform is designed so that sites and study teams access all Suvoda products through a single login, reducing the credential management burden that contributes to site fatigue in multi-vendor trial environments.